Editorial Commentary: Could Biological Treatments Be the Game-Changing Factor for Osteoarthritis?

The realization of the presence of an inflammatory component in cartilage degeneration together with the promising application of platelet-rich plasma and amnion as "healing agents" opened a new window of opportunity for biological treatments in osteoarthritis. If the goal is to delay or even cease the degenerative process, then treating the cause rather than the symptom is a key factor for this biological intervention to be successful. As new biological agents arise, there are 3 crucial milestones that need to be met in laboratory and clinical studies: safety, reasonable cost, and improved effectiveness in comparison with alternatives.